{"downloaded": true, "htmlmade": false, "full": {"id": "33443131", "source": "MED", "pmid": "33443131", "pmcid": "PMC8055329", "fullTextIdList": {"fullTextId": "PMC8055329"}, "doi": "10.1212/wnl.0000000000011411", "title": "Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease.", "authorString": "Maple-Gr\u00f8dem J, Dalen I, Tysnes OB, Macleod AD, Forsgren L, Counsell CE, Alves G.", "authorList": {"author": [{"fullName": "Maple-Gr\u00f8dem J", "firstName": "Jodi", "lastName": "Maple-Gr\u00f8dem", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0001-7142-0078"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden. jodi.maple@uis.no."}}}, {"fullName": "Dalen I", "firstName": "Ingvild", "lastName": "Dalen", "initials": "I", "authorId": {"@type": "ORCID", "#text": "0000-0002-8160-3211"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}, {"fullName": "Tysnes OB", "firstName": "Ole-Bj\u00f8rn", "lastName": "Tysnes", "initials": "OB", "authorId": {"@type": "ORCID", "#text": "0000-0002-7230-6426"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}, {"fullName": "Macleod AD", "firstName": "Angus D", "lastName": "Macleod", "initials": "AD", "authorId": {"@type": "ORCID", "#text": "0000-0002-6284-4239"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}, {"fullName": "Forsgren L", "firstName": "Lars", "lastName": "Forsgren", "initials": "L", "authorId": {"@type": "ORCID", "#text": "0000-0002-6458-8398"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}, {"fullName": "Counsell CE", "firstName": "Carl E", "lastName": "Counsell", "initials": "CE", "authorId": {"@type": "ORCID", "#text": "0000-0001-6622-7839"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}, {"fullName": "Alves G", "firstName": "Guido", "lastName": "Alves", "initials": "G", "authorId": {"@type": "ORCID", "#text": "0000-0003-0630-2870"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-6622-7839"}, {"@type": "ORCID", "#text": "0000-0001-7142-0078"}, {"@type": "ORCID", "#text": "0000-0002-6284-4239"}, {"@type": "ORCID", "#text": "0000-0002-6458-8398"}, {"@type": "ORCID", "#text": "0000-0002-7230-6426"}, {"@type": "ORCID", "#text": "0000-0002-8160-3211"}, {"@type": "ORCID", "#text": "0000-0003-0630-2870"}]}, "dataLinksTagsList": {"dataLinkstag": ["altmetrics", "supporting_data"]}, "journalInfo": {"issue": "7", "volume": "96", "journalIssueId": "3113802", "dateOfPublication": "2021 Feb", "monthOfPublication": "2", "yearOfPublication": "2021", "printPublicationDate": "2021-02-01", "journal": {"title": "Neurology", "ISOAbbreviation": "Neurology", "medlineAbbreviation": "Neurology", "NLMid": "0401060", "ISSN": "0028-3878", "ESSN": "1526-632X"}}, "pubYear": "2021", "pageInfo": "e1036-e1044", "abstractText": "<h4>Objective</h4>To establish the significance of glucocerebrosidase gene (<i>GBA</i>) carrier status on motor impairment in a large cohort of patients with incident Parkinson disease (PD).<h4>Methods</h4>Three European population-based studies followed 528 patients with PD from diagnosis. A total of 440 with genomic DNA from baseline were assessed for <i>GBA</i> variants. We evaluated motor and functional impairment annually using the Unified Parkinson's Disease Rating Scale (UPDRS) motor and activities of daily living (ADL) sections. Differential effects of classes of <i>GBA</i> variants on disease progression were evaluated using mixed random and fixed effects models.<h4>Results</h4>A total of 387 patients with idiopathic disease (age at baseline 70.3 \u00b1 9.5 years; 60.2% male) and 53 <i>GBA</i> carriers (age at baseline 66.8 \u00b1 10.1 years; 64.2% male) were included. The motor profile of the groups was clinically indistinguishable at diagnosis. <i>GBA</i> carriers showed faster annual increase in UPDRS scores measuring ADL (1.5 point per year, 95% confidence interval [CI] 1.1-2.0) and motor symptoms (2.2 points per year, 95% CI 1.3-3.1) compared to noncarriers (ADL, 1.0 point per year, 95% CI 0.9-1.1, <i>p</i> = 0.003; motor, 1.3 point per year, 95% CI 1.1-1.6, <i>p</i> = 0.007). Simulations of clinical trial designs showed that recruiting only <i>GBA</i> carriers can reduce trial size by up to 65% compared to a trial recruiting all patients with PD.<h4>Conclusion</h4><i>GBA</i> variants are linked to a more aggressive motor disease course over 7 years from diagnosis in patients with PD. A better understanding of PD progression in genetic subpopulations may improve disease management and has direct implications for improving the design of clinical trials.", "affiliation": "From The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Department of Research, Section of Biostatistics (I.D.), and Department of Neurology (G.A.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (J.M.-G., G.A.), University of Stavanger; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (O.-B.T.), University of Bergen, Norway; Institute of Applied Health Sciences (A.D.M., C.E.C.), University of Aberdeen, UK; and Department of Clinical Science, Neurosciences (L.F.), Ume\u00e5 University, Sweden. jodi.maple@uis.no.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "PCL/17/10", "agency": "Chief Scientist Office", "acronym": "CSO_", "orderIn": "0"}, {"grantId": "SGL016\\1041", "agency": "Academy of Medical Sciences", "acronym": "AMS_", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Parkinson Disease", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease Progression"}, {"majorTopic_YN": "N", "descriptorName": "Genetic Predisposition to Disease"}, {"majorTopic_YN": "N", "descriptorName": "Glucosylceramidase", "meshQualifierList": {"meshQualifier": {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "Y", "descriptorName": "Activities of Daily Living"}, {"majorTopic_YN": "Y", "descriptorName": "Genotype"}, {"majorTopic_YN": "Y", "descriptorName": "Mutation"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Mental Status and Dementia Tests"}]}, "chemicalList": {"chemical": {"name": "Glucosylceramidase", "registryNumber": "EC 3.2.1.45"}}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1212/WNL.0000000000011411"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8055329"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8055329?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "refsnp"}, "dateOfCompletion": "2021-03-02", "dateOfCreation": "2021-01-14", "firstIndexDate": "2021-01-16", "fullTextReceivedDate": "2021-04-28", "dateOfRevision": "2021-04-21", "electronicPublicationDate": "2020-12-21", "firstPublicationDate": "2020-12-21"}, "htmllinks": "https://europepmc.org/articles/PMC8055329", "abstract": "<h4>Objective</h4>To establish the significance of glucocerebrosidase gene (<i>GBA</i>) carrier status on motor impairment in a large cohort of patients with incident Parkinson disease (PD).<h4>Methods</h4>Three European population-based studies followed 528 patients with PD from diagnosis. A total of 440 with genomic DNA from baseline were assessed for <i>GBA</i> variants. We evaluated motor and functional impairment annually using the Unified Parkinson's Disease Rating Scale (UPDRS) motor and activities of daily living (ADL) sections. Differential effects of classes of <i>GBA</i> variants on disease progression were evaluated using mixed random and fixed effects models.<h4>Results</h4>A total of 387 patients with idiopathic disease (age at baseline 70.3 \u00b1 9.5 years; 60.2% male) and 53 <i>GBA</i> carriers (age at baseline 66.8 \u00b1 10.1 years; 64.2% male) were included. The motor profile of the groups was clinically indistinguishable at diagnosis. <i>GBA</i> carriers showed faster annual increase in UPDRS scores measuring ADL (1.5 point per year, 95% confidence interval [CI] 1.1-2.0) and motor symptoms (2.2 points per year, 95% CI 1.3-3.1) compared to noncarriers (ADL, 1.0 point per year, 95% CI 0.9-1.1, <i>p</i> = 0.003; motor, 1.3 point per year, 95% CI 1.1-1.6, <i>p</i> = 0.007). Simulations of clinical trial designs showed that recruiting only <i>GBA</i> carriers can reduce trial size by up to 65% compared to a trial recruiting all patients with PD.<h4>Conclusion</h4><i>GBA</i> variants are linked to a more aggressive motor disease course over 7 years from diagnosis in patients with PD. A better understanding of PD progression in genetic subpopulations may improve disease management and has direct implications for improving the design of clinical trials.", "pdflinks": "https://europepmc.org/articles/PMC8055329?pdf=render", "journaltitle": "Neurology", "authorinfo": ["Maple-Gr\u00f8dem J", "Dalen I", "Tysnes OB", "Macleod AD", "Forsgren L", "Counsell CE", "Alves G"], "title": "Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease."}